Combination chemotherapy of oral 5′-deoxy-5-fluorouridine and cisplatin in advanced gastric cancer : A phase II study

Journal of Korean Medical Science

Volumn 13, Issue 6, 1998, Pages 612-616

  Ahn, Myung Ju ^a   Han, Dong Su ^a   Sohn, Joo Hyun ^a   Jeon, Yong Cheol ^a   Jun, Dae Won ^a   Choi, Nak Won ^a   Park, Hwon Kyum ^a   Baik, Hong Kyu ^a   Lee, Hong Gi ^a   Nam, Young Soo ^a   Choi, Il Young ^a  

^a Hanyang University   (South Korea)

Author keywords

5 DFUR; Cisplatin; Combination; Drug therapy; Floxuridine; Stomach neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXIFLURIDINE; FLOXURIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; STOMACH TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOXURIDINE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 0032239996     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.1998.13.6.612     Document Type: Article

References (28)

1. Cook AF, Holman MJ, Kramer MJ, Trown PW. Fluorinated pyrimidine nucleosides: III. Synthesis and antitumor activity of a series of 5′-deoxy-5-fluoropyrimidine nucleosides. J Med Chem 1979; 22: 1330-5.
2. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H. Activation of 5′-deoxy-5-fluorouridine by thymidine phophorylase in human tumors. Chem Pharma Bull 1983; 31: 175-8.
3. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama HB. Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 1980; 71: 112-23.
4. Miwa M, Cook A, Ishitsuka H. Enzymatic cleavage of various fluorinated pyrimidine nucleosides to 5-fluorouracil and their antiproliferative activities in human and murine tumor cells. Chem Pharm Bull (Tokyo) 1986; 34: 4225.
5. Armstrong RD, Diasio RB. Metabolism and biological activity of 5′-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res 1980; 40: 3333-8.
6. Uehara N, Baba H, Nitta K, Kunimoto T, Takeuchi M, Sasaki T. The therapeutic effects of orally administered 5′-deoxy-5-fluorouridine, 1-(2-tetrahydrofuryl)-5-fluororouracil and 5-fluorouracil on experimental murine tumors. Gann 1985; 76: 1034-41.
7. Kimura K, Saito T, Taguchi T. Experimental and clinical studies on the anticancer agent doxifluridine (5′-DFUR). J Int Med Res 1988; 16(Suppl 2): 1B-37B.
8. Bollag W, Hartmann HR. Tumor inhibitory effects of a new fluorouracil derivative: 5-deoxy-5-fluorouridine. Eur J Cancer 1980; 16: 427-32.
9. Ohta Y, Sueki K, Kitta K, Takemoto K, Ishitsuka H, Yagi Y. Comparative studies on the immunosuppressive effect among 5′-deoxy-5-fluorouridine, ftorafur and 5-fluorouracil. Gann 1980; 71: 190-6.
10. Kramer MJ, Trown PW, Cleeland R, Cook AF, Grunberg E. 5′-deoxy-5-fluorouridine- a new orally active antitumor agent. Comparative activity with 5-fluorouracil, 2′-deoxy-5′-deoxyfluorouridine and ftorafur against transplantable tumors in mice and rats. Proc Am Assoc Cancer Res 1979; 20: 20.
11. Alberto P, Mermillod B, Germano G. A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. Eur J Cancer Clin Oncol 1988; 24: 559-63.
12. Au JL, Wientjes MG, Bramer SL. Effect of uridine coadministration on 5′-deoxy-5-fluorouridine disposition in rats. Cancer Chemother Pharmacol 1988; 22: 5-10.
13. Trave F, Cannobbio L, Lai-Sam AJ. Role of administration route in the therapeutic efficacy of doxifluridine. J Natl Cancer Inst 1987; 78: 527-32.
14. Yoshimori K, Hasegawa K, Niitani H. Study on efficacy and safety of 5-deoxy-5-fluorouridine with intermittent administration. In: Berkarda P, ed. Progress in antimicrobial and anticancer chemotherapy. Landsberg (Germany): Ecomed, 1987; 3: 493-5.
15. Alberto P, Winkelmann JJ, Pschoud N. Phase I study of oral doxifluridine using two schedules. Eur J Cancer Clin Oncol 1989; 25: 905-8.
16. Leichman L, Berry BT. Cisplatin therapy for adenocarcinoma of the stomach. Semin Oncol 1991; 18: 25-31.
17. Rougier PH, Ducreux M, Mahjoubi M. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994; 30A: 1263-9.
18. Ohtsu A, Shimada Y, Yoshida Y. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from Japan Clinical Oncology Group (JCOG). Eur J Cancer 1994; 30A: 2091-3.
19. Wakui A. Phase II trial of 5′-deoxy-5-fluorouridine in the treatment of gastric cancer: a multicenter cooperative study. J Int Med Res 1988; 16(Suppl 2): 17B-18B.
20. Koizumi W, Kurihara M, Sasai T, Yoshida S, Morise K, Imamura A. A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 1993; 72: 658-62.
21. Wils JA, Klein HO, Wagner DJT. Sequential high dose methotrexate and fluorouracil combined with daxorubicin- a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827-31.
22. Findlay M, Cunningham D, Norman A. A phase II trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-7.
23. Cascinu S, Fedeli A, Luzi S. Intensive weekly chemotherapy for advanced gastric cancer with 5-fluourourcail, cisplatin, epi-doxorubicin, 6S-leucovorin and granulocyte-colony stimulating factor. Int J Oncol 1993; 3: 535-8.
24. Zaniboni A, Barni S, Labianca R. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. Cancer 1995; 76: 1694-9.
25. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989; 7: 1310-7.
26. Lerner A, Gonin R, Steele GD. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 1992; 10: 536-40.
27. Bajetta E, Di Bartolomeo M, de Braud F, Bozzetti F, Bochicchio AM, Comella P, Fagnani D, Farina G, Ferroni C, Franchi R. Etoposide, doxorubicin and cisplatin treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology Group. Eur J Cancer 1994; 30A: 596-600.
28. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541-8.